2022: The End Of The US Price Negotiation Debate?
The Democratic party has been advocating for Medicare drug price negotiation authority in the US for almost two decades. The coming year may see it finally happen – or it might mean the issue is gone for good.
You may also be interested in...
Biopharma analysts discuss the likely impact of the drug pricing reform provisions in the Build Back Better legislation, which has hit a roadblock created by Democratic Senator Joe Manchin of West Virginia.
Score of slimmed down Medicare negotiations in the Build Back Better legislation is $79bn, a far cry from the $456bn in savings projected from the draconian HR 3. But the bill’s overall impact on the deficit means that pharma might get a total reprieve – or go back on the chopping block.
Four House hearings show how far away even many Democrats are from supporting a single payer system in the US.